Towards Healthcare
Cell and Gene Therapy Market Business Expansion Insight by 2034

Cell and Gene Therapy Market to Hit $187.44 Billion by 2034

The report covers Cell and Gene Therapy Market Top Companies and Shares including Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., CORESTEM Inc., Dendreon Pharmaceuticals LLC., Helixmith Co. Ltd., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG and Pfizer Inc. Geographically it covers North America, Europe, Asia Pacific, Latin America and MEA. The report offers the value (in USD Billion) for the above segments.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Cell and Gene Therapy Market Assessment

  • Overview
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA

North America Cell and Gene Therapy Market Assessment

  • Overview
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Europe Cell and Gene Therapy Market Assessment

  • Overview
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Asia Pacific Cell and Gene Therapy Market Assessment

  • Overview
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Latin America Cell and Gene Therapy Market Assessment

  • Overview
  • Latin America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Latin America  Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Latin America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Latin America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

MEA Cell and Gene Therapy Market Assessment

  • Overview
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Company Profiles

  • Alnylam Pharmaceuticals Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Amgen Inc.
  • Biogen Inc.
  • CORESTEM Inc.
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co. Ltd.
  • JCR Pharmaceuticals Co. Ltd.
  • Kolon TissueGene Inc.
  • Novartis AG
  • Pfizer Inc.

Conclusion & Recommendations

  • Insight Code: 5052
  • No. of Pages: 150
  • Format: PDF/PPT/Excel
  • Published: November 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Cell and gene therapy has shown promise in the treatment of various diseases, including genetic disorders, cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. Specific examples include inherited genetic disorders like cystic fibrosis and sickle cell anemia, certain types of leukemia and lymphoma, and neurodegenerative conditions like Parkinsos and Alzheimers diseases.

Like any medical intervention, cell and gene therapy carries certain risks and potential side effects. These can include immune reactions, inflammation, infection, or the possibility of unexpected outcomes. However, rigorous safety assessments and monitoring protocols are in place to minimize these risks. Clinical trials and regulatory approvals ensure that therapies are thoroughly evaluated for their safety and efficacy before being made available to patients.

Cell and gene therapy offers several benefits. It has the potential to provide targeted and personalized treatments, especially for genetic disorders and certain types of cancer. These therapies can address unmet medical needs, improve patient outcomes, and potentially offer long-term or curative solutions. They also have the advantage of being less invasive than traditional treatments, reducing the need for prolonged hospital stays and minimizing side effects.

American Society of Cell + Gene Therapy, U.S. Food & Drug Administration, National Library of Medicine, and American Cancer Society

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 509

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 509